Drug Trial Radar · NCT07062198
Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's Disease
Last checked: Nov 19, 2026Latest source record: Feb 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
845
Planned (sponsor's estimate)
Start
Sep 12, 2025
Primary completion
Sep 2026
Study completion Sep 2026
Sponsor
- Lead sponsor
- ScandiBio Therapeutics ABIndustry
- Sponsor type
- Industry
- First posted
- Jul 14, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Supportive care
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomised, double-blinded, placebo-controlled study aims to establish metabolic improvements in subjects diagnosed with Alzheimer's Disease (AD) by treatment with CMA2 including N-acetyl-L-cysteine (NAC), L-carnitine-L-tartrate (LCAT), nicotinamide (niacinamide), and L-serine. Participants will take the drug CMA2 or a placebo twice a day for 26 weeks. They will visit the clinic 4 times for checkups and tests.
Conditions
- Alzheimer Disease
Interventions
Combined metabolic activatorsDrug
A total of 20g of CMA2 with strawberry aroma and colouring agent will be given. The IMP will be provided as a soluble powder packed as individual dosages in identical sachets. The powder should be dissolved in 200 ml preferably cold water before use. The powder can also be used on yoghurt or other food. The subjects will take two daily oral doses of the IMP, one dose just after breakfast and one dose just after dinner. Subjects who cannot tolerate (e.g., diarrhoea) taking full dose will be withdrawn from the study.
Collagen and maltodextrinOther
As placebo, a total of 20g of compound primarily containing collagen and maltodextrin will be administered. Placebo contains strawberry aroma flavouring and colouring agent.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog) score from baseline to end-of-treatmentTime frame: Visit 1, Visit 5 (13 weeks), Visit 8 (26 weeks)
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Department of Neurology and Neuroscience, Faculty of Medicine, Alaaddin Keykubat University
Alanya, Turkey (Türkiye) · Recruiting
Ataturk University, Faculty of Medicine, Department of Neurology, Erzurum, Turkey; Movement Disorders and Neuromodulation Center, Ataturk University
Erzurum, Turkey (Türkiye) · Recruiting
Behavioural Neurology and Movement Disorders Unit, Department of Neurology, Istanbul Faculty of Medicine, Istanbul University
Istanbul, Turkey (Türkiye) · Recruiting
Haydarpaşa Numune Training and Research Hospital, University of Health Sciences Istanbul
Istanbul, Turkey (Türkiye) · Not yet recruiting
Sancaktepe Şehit Prof. Dr. İlhan Varank Training and Research Hospital, University of Health Sciences Istanbul
Istanbul, Turkey (Türkiye) · Recruiting
SB Haseki Training and Research Hospital, Istanbul, University of Health Sciences Istanbul
Istanbul, Turkey (Türkiye) · Recruiting
Sultan Abdülhamid Han Training and Research Hospital, University of Health Sciences Istanbul
Istanbul, Turkey (Türkiye) · Recruiting
Umraniye Training and Research Hospital, University of Health Sciences Istanbul
Istanbul, Turkey (Türkiye) · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.